KiwiNet — New Zealand's National Research-Commercialisation Network

KiwiNet (Kiwi Innovation Network Limited) was established in 2011 to pool New Zealand's government PreSeed Accelerator Fund and share commercialisation expertise nationally, building on UniCom, a 2008 consortium of four university tech-transfer offices. It is a shareholder company owned by New Zealand universities, Crown Research Institutes and other public research organisations, together representing roughly 80% of the country's publicly funded researchers.

To pool national pre-seed research-commercialisation funding and expertise across New Zealand's public research sector, turning publicly funded research into start-ups, licences and commercial deals.

KiwiNet's 2024 annual report (to 30 June 2024) records 82 start-up companies and $560 million in cumulative financial returns since 2011. In its 2019 funding round, MBIE approved NZ$9,944,920 (excluding GST) over two years for KiwiNet. A named success story on KiwiNet's own site, Zincovery (a University of Canterbury spin-out founded 2021), received NZ$267,000 in PreSeed funding, has since raised NZ$20 million in total, and signed over NZ$500 million in global commercial agreements.

An independent evaluation commissioned by New Zealand's Ministry of Business, Innovation and Employment (MBIE), conducted by Ridley Insights in 2014, found that 573 PreSeed-funded projects since 2004 had received NZ$42.6 million in government investment, matched by a further NZ$90.9 million in co-funding, generating 386+ licences plus start-ups and commercial deals.

KiwiNet's own 2025 Shareholder Vision Statement is candid that 'less than 1% of public research funding goes toward commercialisation' in New Zealand, citing TTO funding instability, a shallow early-stage investment market, and system fragmentation as ongoing constraints — with the country's overall R&D spend sitting at roughly 0.95% of GDP, well below the government's 2% target. In 2026, KiwiNet's CEO publicly warned that new science-system funding reforms redirecting NZ$111 million toward 'advanced technology' by cutting other research budgets risk treating commercialisation 'as a zero-sum exercise' that undermines the upstream research pipeline it depends on.